Compare Cenovus Energy Inc (CVE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs ResMed Inc. — how do they compare? Cenovus Energy Inc trades at $30.25 (market cap $55.00B), while ResMed Inc. trades at $225.04 (market cap $32.61B). The key difference: Cenovus Energy Inc is the larger of the two by market cap, and Cenovus Energy Inc pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| CVE | RMD | |
|---|---|---|
Market Cap | $55.00B | $32.61B |
Sector | Energy | Health |
52-Week High | $31.80 | $293.73 |
52-Week Low | $14.83 | $182.82 |
Enterprise Value | $61.08B | $31.97B |
Dividend Yield | 2.09% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.2, up 2.17% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, matching estimates with $1.11 EPS, and raised full-year production guidance. Valuation ratios appear attractive with a P/E of 11.56 and EV/EBITDA of 5.77, while profitability remains solid with an 11.48% net income margin and 20.96% ROE.
Outlook is positive driven by higher oil prices and record oil sands production, but risks include commodity price volatility and refining margin pressures. Analyst consensus leans bullish with 11 Buy ratings, though geopolitical tensions and Canadian regulations pose headwinds for sustained growth.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
